Camurus AB (CAMRF)
OTHER OTC:CAMRF
CAMRF Stock Chart & Stats
$68.85
$0.00(0.00%)
At close: 4:00 PM EST
$68.85
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$43.60 - $80.25
Previous CloseN/A
Volume89.00
Average Volume (3M)31.00
Market Cap
$2.89B
Enterprise Value$22.49B
Total Cash (Recent Filing)$3.73B
Total Debt (Recent Filing)$106.03M
Price to Earnings (P/E)49.6
Beta0.70
Next Earnings
May 12, 2026EPS Estimate
0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.18
Shares Outstanding59,934,734
10 Day Avg. Volume15
30 Day Avg. Volume31
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)8.62
Price to Sales (P/S)16.11
P/FCF Ratio49.93
Enterprise Value/Market Cap7.78
Enterprise Value/Revenue9.93
Enterprise Value/Gross Profit10.70
Enterprise Value/Ebitda23.33
Forecast
1Y Price Target
$73.09Price Target Upside6.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.75
Revenue Forecast (FY)$308.49M
Bulls Say, Bears Say
Bulls Say
High, Stable Gross MarginsSustained gross margins near 90% reflect strong product economics from long‑acting formulations and proprietary delivery technology. This durable margin base supports long‑term profitability, funds reinvestment in R&D/commercial expansion, and cushions operating leverage.
Strong Cash GenerationRobust and improving operating and free cash flow provides organic funding for launches, milestone investments, and R&D. High cash conversion reduces dependence on external financing and gives management flexibility to execute U.S. expansion and partner deals over the medium term.
Conservative Balance Sheet, Very Low LeverageA very low debt load provides financial flexibility and downside protection, enabling the company to absorb launch costs or delayed milestone timing. This conservative capital structure supports strategic optionality and resilience through clinical and market‑access cycles.
Bears Say
Inconsistent Top‑line GrowthVolatile revenue trends weaken predictability of earnings and cash flow, complicating funding for launches and R&D. Reliance on a few key products and milestone timings means growth can swing materially year‑to‑year, raising execution risk for sustaining longer‑term expansion.
Market‑access/reimbursement ConstraintsStructural reimbursement and funding barriers in major European markets limit addressable patient uptake and prolong commercialization timelines. Even with clinical efficacy, persistent policy, funding and remuneration issues can cap revenue potential and slow scaling across core geographies.
Planned Higher Operating Expenses For U.S. LaunchMaterial planned OpEx increases to support a U.S. launch and elevated R&D raise near‑term cost and margin pressure. Execution risk on commercialization and timing of returns (sales, milestones) could temporarily erode profitability and strain resource allocation if uptake is slower than modeled.
Camurus AB News
CAMRF FAQ
What was Camurus AB’s price range in the past 12 months?
Camurus AB lowest stock price was $43.60 and its highest was $80.25 in the past 12 months.
What is Camurus AB’s market cap?
Camurus AB’s market cap is $2.89B.
When is Camurus AB’s upcoming earnings report date?
Camurus AB’s upcoming earnings report date is May 12, 2026 which is in 48 days.
How were Camurus AB’s earnings last quarter?
Camurus AB released its earnings results on Feb 12, 2026. The company reported $0.179 earnings per share for the quarter, missing the consensus estimate of $0.254 by -$0.075.
Is Camurus AB overvalued?
According to Wall Street analysts Camurus AB’s price is currently Undervalued.
Does Camurus AB pay dividends?
Camurus AB does not currently pay dividends.
What is Camurus AB’s EPS estimate?
Camurus AB’s EPS estimate is 0.38.
How many shares outstanding does Camurus AB have?
Camurus AB has 59,934,734 shares outstanding.
What happened to Camurus AB’s price movement after its last earnings report?
Camurus AB reported an EPS of $0.179 in its last earnings report, missing expectations of $0.254. Following the earnings report the stock price went down -18.521%.
Which hedge fund is a major shareholder of Camurus AB?
Currently, no hedge funds are holding shares in CAMRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Camurus AB
Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
CAMRF Company Deck
CAMRF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly positive strategic and financial picture for Camurus: full-year revenue and operating profitability improved materially, net cash increased significantly, regulatory approvals and U.S. FDA acceptance (PDUFA set) support upcoming launches, Brixadi royalties showed strong growth, and early-stage R&D (CAM2056) delivered compelling data. At the same time, the company faces notable short-term headwinds: Q4 revenue and product sales were down due to a U.K. distribution change and FX effects, quarter operating profit contracted, access/reimbursement barriers in several large European markets constrain Buvidal upside, and timing uncertainty remains for the SORENTO readout and some milestone revenues. Management provided constructive 2026 guidance while flagging planned increases in OpEx tied to U.S. launch preparation. Overall, strengths in commercial traction, cash position, approvals, and pipeline momentum outweigh the near-term operational and market-access challenges.View all CAMRF earnings summariesCAMRF Stock 12 Month Forecast
Average Price Target
$73.09
▲(6.15% Upside)
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
BioArctic AB Class B
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Ownership Overview
―
Insiders
4.96% Mutual Funds
― Other Institutional Investors
92.11% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---